Understand total and free testosterone, how SHBG affects interpretation, and why test methods, repeat testing and symptoms belong in the same assessment.
Total and free testosterone describe different parts of circulating hormone, and comparing them helps clinicians assess possible deficiency when protein binding complicates the picture.
This article is for informational purposes only and is not medical advice. Personal test interpretation and treatment decisions belong with a qualified clinician.
Total testosterone, often shortened to TT, is the overall concentration of testosterone measured in blood. It includes testosterone bound to proteins as well as the unbound fraction. The European Association of Urology (EAU) uses total testosterone as the primary measurement in its diagnostic recommendations for male hypogonadism.
The distinction matters because a total result counts these fractions together. It does not separate protein-bound hormone from free hormone on its own. A report headed “testosterone” and one headed “free testosterone” are therefore not simply different names for the same measurement.
The word total describes what is counted. It does not mean that the result provides a complete assessment of hormonal health. Its clinical use starts with a reliable measurement and continues with interpretation of the circumstances surrounding it.
The EAU recommends measuring total testosterone between 07:00 and 10:00, while fasting and using a reliable assay. It also recommends repeating a low result on at least two separate occasions before treatment.
These recommendations make the testing process part of the assessment. A clinician reviewing a low result needs to know how it was obtained and whether follow-up measurements support the same finding. The initial value is the beginning of that process rather than its conclusion.
The guideline also emphasizes assay quality and comparability between laboratories. For a clinical discussion, the relevant information includes the report itself and the circumstances of collection. Understanding why a single low reading needs context helps frame that discussion without turning the first result into a treatment decision.
Free testosterone, often shortened to fT, refers to testosterone that is not bound to proteins. Unlike total testosterone, it describes only the unbound fraction rather than the combined concentration.
According to the EAU, clinicians may use free testosterone to help clarify androgen levels when binding proteins affect the interpretation of total testosterone. Its medical use is therefore more specific than simply providing another number on a hormone panel.
Free testosterone is not a different hormone. It is a different fraction of the same circulating testosterone. This distinction helps explain why total and free results answer related questions without being interchangeable.
The EAU distinguishes between methods that measure the unbound fraction and methods that estimate it:
That distinction makes the method part of the result. The words “free testosterone” on a report do not establish how the value was obtained. A measured result and a calculated result have different routes to assessing the same fraction.
For a calculated value, the relevant accompanying information includes the total testosterone and binding-protein measurements used in the calculation. For a measured value, the relevant question is which assay was used. This is why the laboratory method behind a free result belongs in the conversation alongside the number itself.
Sex hormone-binding globulin, or SHBG, is a binding protein that helps explain the relationship between total and free testosterone. The EAU notes that total testosterone values can change as SHBG changes. It recommends considering SHBG measurement and free-testosterone calculation when conditions associated with altered SHBG are present.
This creates an important distinction between the two tests. Total testosterone includes protein-bound hormone, while free testosterone focuses on the unbound fraction. A change in the binding context can therefore make the total result less straightforward to interpret on its own.
SHBG is not a competing testosterone measurement. It supplies information about the binding context in which the testosterone measurements sit. Albumin is another input in the free-testosterone calculation identified by the EAU.
The EAU lists factors associated with changes in either direction:
These associations help identify when further assessment may be useful. They do not provide a way to predict an individual's free testosterone from a health condition alone. The guideline's approach is to measure the relevant biomarkers when indicated rather than infer the result from the association.
This is also why the comparison is not a contest to find the “better” testosterone number. Total testosterone provides the broad blood measurement. Free testosterone adds a view of the unbound fraction when the binding context makes that information relevant.
A useful way to understand SHBG's role in reading a hormone panel is to treat it as context connecting the results rather than another isolated flag to interpret.
The EAU says diagnosis of late-onset hypogonadism should combine relevant signs or symptoms with consistently low serum testosterone. It also cautions that symptoms associated with hypogonadism are not exclusive to the condition.
This places laboratory results and symptoms in the same assessment. Neither a symptom by itself nor an isolated laboratory flag establishes the diagnosis. The clinician's task is to determine whether the clinical and biochemical findings support one another.
As a clinical benchmark, the EAU identifies 12 nmol/L (3.5 ng/mL) as a reliable total-testosterone threshold for diagnosing late-onset hypogonadism. It says the threshold should be integrated with the person's symptoms and clinical profile.
For free testosterone, the EAU says limited evidence supports considering 220 pmol/L (6.4 ng/dL) a reliable threshold in the relevant clinical setting. This should not be presented as a universal cutoff independent of symptoms or the laboratory context. The assay method and laboratory reference interval also matter when interpreting it.
The practical distinction is between a benchmark and an individual conclusion. A threshold helps organize a clinical assessment. It does not remove the need to establish why the test was ordered and whether the rest of the assessment supports the finding.
When a total result is near a clinical decision threshold, the useful question is whether SHBG could affect its interpretation. If symptoms and total testosterone appear inconsistent, a clinician may consider whether SHBG measurement and a reliable free-testosterone assessment would clarify the picture.
The EAU recommends checking for accompanying diseases and for drugs or substances that may interfere with testosterone production or action. This means a hormone result belongs alongside a medical history rather than apart from it.
Relevant discussion therefore includes symptoms and health conditions as well as medication or substance use. These details help the clinician assess the result in context. They are not reasons to change medication or begin hormone treatment without personal medical review.
The same principle applies when someone already has both total and free results. Having more measurements does not eliminate the need to understand the clinical question. The purpose is to clarify the assessment, not to select whichever value seems most reassuring or most concerning.
A focused clinical discussion can bring the different pieces together:
These questions follow the guideline's assessment framework without assuming that everyone needs every available hormone test. They also keep the discussion focused on why additional information would help rather than on collecting numbers without a clear clinical purpose.
Total testosterone describes the combined circulating concentration, while free testosterone adds context about the unbound fraction; both belong within an assessment of binding proteins and the person's clinical picture.
Treating a free testosterone flag as a verdict can leave protein binding and test methods out of the picture, a shortcut Testostra avoids through evidence-led explanations. Its biomarker coverage helps men distinguish total hormone measurements from the unbound fraction and understand SHBG while keeping education separate from personal diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra